• Profile
Close

Glucagonostatic potency of GLP-1 in patients with type 2 diabetes, patients with type 1 diabetes, and healthy control individuals

Diabetes May 28, 2021

Bagger JI, Grondahl MFG, Lund A, et al. - The present study was performed to explore the dose-response relationship for glucagon-like peptide 1 (GLP-1) on glucose-induced glucagon suppression in healthy individuals and patients with type 2 and type 1 diabetes. Researchers included 10 healthy individuals with normal glucose tolerance, 10 patients with type 2 diabetes, and 9 C-peptide–negative patients with type 1 diabetes who had undergone 4 separate stepwise glucose clamps (five 30-min steps from fasting level to 15 mmol/L plasma glucose) during simultaneous intravenous infusions of saline or 0.2, 0.4, or 0.8 pmol GLP-1/kg/min. During a stepwise glucose clam, the glucagonostatic potency of GLP-1 is preserved in patients with type 2 diabetes, whereas the individuals with type 1 diabetes were insensitive to the glucagonostatic effects of both glucose and GLP-1.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay